The FDA approved Merck combination pill Janumet, for type 2 diabetes.
The drug contains Merck’s sitagliptin—the active ingredient in Januvia—and an older glucose-lowering agent called metformin.
Januvia, part of a class of drugs called DPP-4 inhibitors, was approved in October. It enhances the body’s own ability to lower blood sugar levels. Novartis is seeking FDA approval for its own DPP-4 inhibitor, Galvus, but an FDA request for more data has delayed launch.